ATRICURE $9.00

down -0.12


19/6/2013 04:19 PM  |  NASDAQ : ATRC  |  Industries : Manufacturing / Medical Equipment and Supplies Manufacturing
Last Trade: 9.00
Trade Time: Jun 19 4:00 PM Eastern Daylight Time
Change: -0.12 (-1.32 %)
Prev Close: 9.12
Open: 9.09
Bid: 7.00
Ask: 9.08
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get ATRC Trend Analysis - it has underperformed the S&P 500 by 27%

ETF Alternatives



People viewing ATRC also viewed: , , , ,

Competitors

Ticker Name Volume % Change
CPCF CPC OF AMERICA; INC. 1.6K +0.65%
RMCP REVOLUTIONS MEDICAL 789.2K +0.41%
DYXC DIASYS 20.0K +0.25%
SPHE SPEARHEAD LIMITED 55.0K +0.25%
CYOE CYTOCORE 54.8K +0.20%

Insider Transactions

Date Name Title Volume Trade Price Holding Change
6/14/2013 JOHNSTON RICHARD M Senior Executive Officer -2,383 $9.03 -5.12%
6/14/2013 JOHNSTON RICHARD M Senior Executive Officer -40,165 $9.03 -5.12%
6/13/2013 JOHNSTON RICHARD M Senior Executive Officer -2,971 $8.92 -6.00%
6/13/2013 JOHNSTON RICHARD M Senior Executive Officer -50,079 $8.92 -6.00%
6/12/2013 JOHNSTON RICHARD M Senior Executive Officer -1,373 $9.01 -2.70%
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (ATRC), click here.
View All

ATRC Stock Analysis

  1. Positive Data for COV's Solitaire - Analyst Blog

    (SYK,COV,HAE,ATRC )
    Covidien presented encouraging data at the 2013 ESC regarding the superiority of its Solitaire FR device for acute ischemic stroke treatment.
  2.

    Abbott Progresses with Absorb in Japan - Analyst Blog

    (ABT,ABBV,BAXS,ATRC )
    Abbott Labs (ABT) recently announced that it has initiated a randomized controlled study in Japan to evaluate Absorb, its bioresorbable vascular scaffold (BVS) device, in patients suffering from coronary artery disease (CAD).

  3. FDA Nod for STJ's Ellipse & Assura - Analyst Blog

    (STJ,BAXS,HAE,ATRC )
    St. Jude has won the U.S. FDA approval for its Ellipse and SJM Assura portfolio of ICDs and CRT-Ds.
  4.

    Symmetry Provides Dismal 2013 View - Analyst Blog

    (SMA,HAE,BAXS,ATRC )
    Symmetry has revised its guidance for 2013 based on the company's disappointing first-quarter results as well as a tempered forecast for the rest of the year.
  5.

    Broad Weakness Makes It Harder To Like St. Jude Today

    (STJ,BSX,MDT,EW,JNJ,ATRC )
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock to own for a little while yet.
Free Reports
  1.

    4 Best Buy ETFs for the Current Market

    Don't miss this FREE Special Report from Forbes' fund and ETF expert Jim Lowell.
  2.

    7 Proven Strategies for Market-Stomping Stocks

    Discover Investing Strategies that will Benefit Every Investor Today!
  3.

    Free Managed Futures Book

    Get the four benefits of managed futures as outlined in this booklet.
Marketplace
Trading Center